Skip to Content

Noxafil Approval History

Noxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Development History and FDA Approval Process for Noxafil

Mar 14, 2014Approval FDA Approves Merck’s Noxafil (posaconazole) Injection
Nov 26, 2013Approval FDA Approves Merck’s Noxafil Delayed-Release Tablets
Sep 15, 2006Approval Noxafil Schering-Plough Corporation - Treatment for Prevention of Invasive Fungal Infections
Jul 13, 2004Schering-Plough Reports Posaconazole NDA Accepted for FDA Review

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.